$931 | SAVE $164 | Single User
$2274 | SAVE $401 | Global License

Ulcerative Colitis: Update Bulletin #1

Ulcerative Colitis: Update Bulletin #1
[Lowest Price Guaranteed: $931]

Published by FirstWord Pharma: 01 Dec 2017 | 197049 | In Stock
Related Topics: Business

Introduction



This edition presents key opinion leader (KOL) views on recent developments in the ulcerative colitis (UC) market. Topics covered include: Takeda and Portal Instruments announcing the production of a needle-free formulation of Entyvio (vedolizumab); Qu Biologics reporting that QBECO achieved high clinical and endoscopic response ratesin a Phase II trial conducted in patients with moderate-to-severe UC; Protagonist Therapeutics announcing the initiation of dosing in a Phase I study of PTG 200, an agent which it is developing in collaboration with Janssen Biotech for inflammatory bowel disease (IBD) and other autoimmune conditions; Weill Cornell Medicine and NewYork-Presbyterian presenting results from a study investigating the use of faecal microbiota transplantation (FMT) in patients with UC.

Business Questions:

Are the new formulations of Entyvio likely to provide any benefit to patients with UC?

Is the development of both a needle-free and subcutaneous formulation of Entyvio necessary?

Does QBECO’s composition, based on enteropathic Escherichia coli components, provide a rational basis for the agent’s development as a UC therapy?

Where is PTG 200 most likely to be positioned within the UC treatment algorithm in the future?

Do KOLs think that the scientific rationale underlying FMT’s activity supports its development as a treatment for UC and/or other diseases?

Do KOLs have any concerns about the safety of the FMT procedure?

Table of Contents
for Ulcerative Colitis: Update Bulletin #1

Additional Details

Publisher

FirstWord Pharma

Publisher Information

Reference

197049 |

Report Format

PDF

FirstWord Pharma Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Ulcerative Colitis - Pipeline Review, H1 2017
Ulcerative Colitis - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical an...
09 May 2017 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2017
The Global Ulcerative Colitis Partnering Terms and Agreements since 2010 report provides understandi...
01 Apr 2017 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2017
The Global Ulcerative Colitis Partnering Terms and Agreements since 2010 report provides understandi...
01 Feb 2017 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Ulcerative Colitis Global Clinical Trials Review, H2, 2016
Ulcerative Colitis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report,...
28 Sep 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
Are UC biosimilars a real or perceived threat to branded drugs?Ulcerative colitis (UC) treatment is ...
01 Sep 2016 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Ulcerative Colitis: Update Bulletin [Feb 2016]
IntroductionGain new KOL insights on the latest events happening in Ulcerative Colitis. Topics cover...
01 Feb 2016 by FirstWord Pharma USD $846 (normally
USD $995)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
Introductionipeline drugs are poised to reshape the way doctors treat ulcerative colitis (UC). But w...
01 Dec 2015 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
IntroductionThe Ulcerative Colitis (UC) treatment market is already undergoing radical change as new...
03 Dec 2014 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info

This report is published by FirstWord Pharma

Download Free Report Summary PDF

Ulcerative Colitis: Update Bulletin #1 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...